Drug Development Course
ID: 75A01RFI250001Type: Special Notice
Overview

Buyer

HEALTH AND HUMAN SERVICES, DEPARTMENT OFADMINISTRATION FOR STRATEGIC PREPAREDNESS AND RESPONSE

NAICS

Professional and Management Development Training (611430)

PSC

EDUCATION/TRAINING- OTHER (U099)

Original Source

https://sam.gov/opp/05bd7fcaadba4e3da8b8e9cbf35e7911/view
Timeline
    Description

    The Department of Health and Human Services, through the Administration for Strategic Preparedness and Response, is seeking qualified contractors to provide an in-person, instructor-led training course titled "Drug Development for Scientists," scheduled for December 3-4, 2024, at the Constitution Center in Washington, DC. The course aims to equip up to 30 participants with essential knowledge on the regulatory, commercial, and scientific aspects necessary for successfully bringing drugs to market, covering topics such as drug discovery pathways, target validation, clinical trial phases, and the differences between academic and industry practices. This initiative underscores the government's commitment to enhancing expertise in the pharmaceutical field, aligning with federal training standards. Interested contractors must submit their responses, including training capabilities, past performance, estimated costs, and trainer resumes, by October 8, 2024, to the primary contact, Janet Alvanzo, at janet.alvanzo@hhs.gov.

    Point(s) of Contact
    Janet Alvanzo
    (202) 934-4198
    janet.alvanzo@hhs.gov
    Devin FitzMaurice, Contracting Officer
    (240) 856-2795
    Devin.FitzMaurice@hhs.gov
    Files
    Title
    Posted
    RFI Drug Development Course.pdf
    The Center for the Biomedical Advanced Research and Development Authority (BARDA) is soliciting contractor responses for an in-person, instructor-led course titled "Drug Development for Scientists," scheduled for December 3-4, 2024, at the Constitution Center in Washington, DC. The training aims to cover regulatory, commercial, and scientific aspects integral to successful drug market entry, with specific learning objectives addressing discovery pathways, drug target validation, clinical trial phases, and the differences between academia and industry. Prospective contractors must supply a qualified instructor, develop compliant course materials, and ensure they have relevant experience and credentials within drug development. Submissions are due by October 8, 2024, and must include a confirmation of training capabilities, past performance, estimated costs, and trainer resumes. This request for information identifies the government's need for specialized training to enhance scientific knowledge in drug development, aiming to foster better understanding and preparation within the field.
    SOO Drug Development Course RFI.pdf
    The Department of Health and Human Services, through the Administration for Strategic Preparedness and Response, is issuing a Request for Information (RFI) regarding a training course titled "Drug Development for Scientists." Scheduled for December 3-4, 2024, at the Constitution Center in Washington, DC, this course aims to offer in-person, instructor-led training to up to 30 participants on the comprehensive processes necessary to bring drugs to market. Key learning objectives include pathways for drug discovery, drug target identification, preclinical development, understanding clinical trial phases, and navigating regulatory approval processes. The training also covers the differences between academic and industry practices and addresses US patents and drug exclusivity. Potential contractors are required to provide credible trainers, each holding a master's degree or higher, with over five years of relevant experience in drug development. All course materials must adhere to Section 508 compliance and be submitted two days prior to the event. This initiative emphasizes the government's commitment to enhancing knowledge and expertise within the pharmaceutical field in alignment with federal training standards.
    Lifecycle
    Title
    Type
    Drug Development Course
    Currently viewing
    Special Notice
    Similar Opportunities
    Chemistry, Manufacturing and Controls and Related Services for Development of Drug Products
    Active
    Health And Human Services, Department Of
    The Department of Health and Human Services, through the National Institutes of Health (NIH), is soliciting proposals for Chemistry, Manufacturing, and Controls (CMC) services related to the development of drug products. The objective of this procurement is to secure high-quality formulated drug products to support preclinical, IND-enabling, and clinical studies, ensuring compliance with current Good Manufacturing Practices (cGMP). This initiative is critical for advancing therapeutic development and enhancing the drug development pipeline, which is vital for public health. Proposals are due by February 3, 2025, with a contract period extending from September 30, 2025, to July 31, 2031, and a maximum funding amount of $49,885,703. Interested parties can reach out to Michelle Cecilia at michelle.cecilia@nih.gov or Valerie Whipple at valerie.whipple@nih.gov for further information.
    Notice of Intent to Sole Source to Inter Agency Institute
    Active
    Dept Of Defense
    The Uniformed Services University of the Health Sciences (USUHS) intends to award a sole-source contract to the Inter Agency Institute for the annual Institute for Federal Health Leaders Course, scheduled from February 3-14, 2025. This procurement aims to provide executive-level training tailored for health and medical professionals, with the Inter Agency Institute being the sole provider of this specialized course, as confirmed through previous collaborations with the Defense Health Agency. The initiative underscores USUHS's commitment to enhancing the education and training of individuals serving in the Uniformed Services, reflecting its unique role in federal health education. Interested parties may submit proposals by December 27, 2024, with the potential for competitive procurement if submissions demonstrate distinct advantages over the sole-source approach; the contract will be awarded in accordance with FAR Parts 12 and 13 procedures.
    In Person and Virtual Training - Health Care Professional
    Active
    Health And Human Services, Department Of
    The Department of Health and Human Services, specifically the Indian Health Service (IHS), is seeking a contractor to provide in-person and virtual training for health care professionals aimed at increasing vaccination uptake among American Indian and Alaska Native (AI/AN) communities. The primary objective is to enhance vaccine confidence and reduce the risk of infectious diseases through comprehensive training programs that include the establishment of a Community of Practice for vaccine communication and tailored strategies for community engagement. This initiative is particularly significant in light of the COVID-19 pandemic's impact on vaccination rates and aims to ensure culturally grounded training and evidence-based practices for health care providers. Interested vendors must submit their quotes by January 9, 2025, with inquiries accepted until December 27, 2024. For further details, contact Darryl Smith at darryl.smith@ihs.gov.
    Continuing Education Units/Continuing Medical Education Units Project
    Active
    Health And Human Services, Department Of
    The Department of Health and Human Services, specifically the Substance Abuse and Mental Health Services Administration (SAMHSA), intends to award a non-competitive contract to the Accreditation Council for Pharmacy Education (ACPE) for a Continuing Education Units (CEU) and Continuing Medical Education Units (CME) project. This procurement, categorized under NAICS code 611710, aims to enhance professional development in healthcare by providing essential educational standards, awarding credits, and ensuring compliance with accreditation criteria over a five-year period from 2025 to 2030. The collaboration with ACPE, the sole entity authorized to approve CEUs for various healthcare disciplines, is crucial for streamlining the accreditation process for SAMHSA’s training programs, thereby meeting licensing requirements and improving workforce competencies. Interested parties can express their capability to respond to this notice by contacting Arun Mathur at arun.mathur@samhsa.hhs.gov.
    NIAID CLINICAL PRODUCTS CENTER (CPC)
    Active
    Health And Human Services, Department Of
    The National Institutes of Health (NIH), specifically the National Institute of Allergy and Infectious Diseases (NIAID), is seeking proposals for a contract to provide pharmacy and pharmaceutical oversight for clinical trials, both nationally and internationally. The primary objective of this contract is to ensure the integrity of study products, participant safety, and compliance with pharmacy and pharmaceutical regulations throughout various NIH-funded clinical trials. This opportunity is critical for maintaining high standards in public health research, as it encompasses a wide range of services including product management, regulatory document maintenance, and clinical laboratory testing. Proposals are due by January 17, 2025, with the contract expected to commence on April 1, 2026, and run through March 31, 2027, potentially extending through 2033. Interested parties can contact Deborah Blyveis at blyveisd@niaid.nih.gov or Emily Bannister at emily.bannister@nih.gov for further information.
    FY25 Bulk Pharma Buy (Materiel)
    Active
    Health And Human Services, Department Of
    The Department of Health and Human Services, specifically the Office of Assistant Secretary for Preparedness and Response (ASPR), is seeking information from vendors regarding the procurement of pharmaceuticals for the Strategic National Stockpile (SNS) under the FY25 Bulk Pharma Buy initiative. The primary objective is to identify suppliers capable of providing FDA-approved medications, including Amoxicillin, Ciprofloxacin, and Clindamycin, in specified formulations and quantities, as detailed in the associated RFI documents. This procurement is crucial for ensuring rapid access to essential medical supplies during public health emergencies, such as biological or chemical threats and natural disasters. Interested vendors must submit their capabilities and relevant information electronically by January 9, 2025, to Terri Reed at terri.reed@hhs.gov, with the understanding that responses will not be returned and will be treated as public knowledge.
    Public Health Industrial Base Capabilities and Capacities: Anti-Microbials
    Active
    Health And Human Services, Department Of
    The Department of Health and Human Services (HHS) is seeking industry partners to provide information regarding domestic production capabilities related to anti-microbials under the Defense Production Act Title III Program. The objective of this Request for Information (RFI) is to identify gaps in the Public Health Industrial Base (PHIB) and enhance national defense resources by focusing on the production of essential medicines and medical countermeasures sourced domestically. Respondents are encouraged to share insights on their manufacturing processes, regulatory compliance, and infrastructure, as well as past supply chain disruptions and investment needs, with responses due by January 6, 2025, at 10 AM ET. Interested parties should submit their responses to Chris Newell at IBMSC-Submissions@hhs.gov.
    ADAPT Contract Research Organization Support Services
    Active
    Health And Human Services, Department Of
    The Department of Health and Human Services, through the National Institutes of Health's Advanced Research Projects Agency for Health (ARPA-H), is seeking feedback on a draft solicitation for the ADAPT Contract Research Organization Support Services. This initiative aims to support a clinical trial framework focused on metastatic cancer treatment, utilizing biomarker-driven strategies to enhance patient outcomes. The contract encompasses a range of services, including data management, biological testing, regulatory support, and logistical capabilities, all while adhering to stringent data protection and confidentiality standards. Interested parties are invited to submit unclassified feedback by December 27, 2024, to Steven Snyder at steven.snyder@arpa-h.gov, with the contract performance period anticipated from March 2025 to February 2030.
    DMDC Fiscal Year (FY) 2025 Training
    Active
    Dept Of Defense
    The Department of Defense, through the Defense Human Resources Activity, is conducting market research for a Fiscal Year 2025 Training Contract aimed at enhancing the skills of Defense Manpower Data Center (DMDC) employees. The procurement seeks vendors capable of providing a comprehensive suite of training programs across 29 courses in areas such as Business Operations, Cybersecurity, Human Resources Development, Innovation, and Technical Operations, with the possibility of consolidating these under a single contract or multiple contracts. This initiative is crucial for improving operational efficiency and effectiveness within the government workforce, ensuring that employees receive the necessary training to meet evolving demands. Interested vendors are encouraged to submit capability statements detailing their qualifications and past experiences by the deadline specified in the SAM system, with inquiries directed to J. Mario Santizo at juan.m.santizo.civ@mail.mil or by phone at 202-913-5967.
    FY25 FDA Broad Agency Announcement (BAA) for Advanced Research and Development of Regulatory Science
    Active
    Health And Human Services, Department Of
    The Department of Health and Human Services, specifically the Food and Drug Administration (FDA), is soliciting proposals through the FY25 Broad Agency Announcement (BAA) aimed at advancing regulatory science and innovation. This opportunity invites organizations, particularly small businesses, to submit research and development proposals that address critical areas such as alternative drug development methods, advanced manufacturing technologies, and predictive toxicology, with a strong emphasis on including diverse populations in research. Proposals must be submitted by February 24, 2025, and will undergo a two-tier evaluation process, with the potential for multiple contracts awarded based on proposal quality and funding availability. Interested parties can contact Ian Weiss at Ian.Weiss@fda.hhs.gov or by phone at 301-796-5728 for further information.